Galectin Therapeutics Inc.GALTNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 82% recommend buying.

Consensus Rating

Buy

11 analysts·Moderate coverage

82%

Rating Distribution

Strong Buy

00%

Buy

982%

Hold

218%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 289% higher.

Bear Case

$11.00

+289%

Consensus

$11.00

+289%

Bull Case

$11.00

+289%

Price Range11 analysts

Low

Consensus

High

$11.00

Current Target

Current Price

$2.83

Upside to Target

$8.17

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.41(1 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+114.39%

EPS—

FY2028

Rev+48.53%

EPS—

FY2029

Rev-95.96%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-3.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 17, 2025H.C. Wainwright

Galectin Therapeutics price target raised to $11 from $6 at H.C. Wainwright

Target:$11.00

+77.4%from $6.20

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance